This book Alternative Splicing and Cancer explores the crucial role alternative splicing, a post-transcriptional process, plays in human health and diseases, particularly cancer. Diving deep into the complexities of gene expression and protein diversity, the book illuminates how abnormal splicing contributes to aggressive tumor formation, affecting cellular functions such as proliferation, survival, and immune evasion. With a focus on understanding molecular mechanisms, this book unravels potential diagnostic and prognostic targets, opening doors for enhanced anti-cancer treatment efficacy. An indispensable resource for anyone intrigued by the interplay between gene splicing and cancer biology, it paves the way towards innovative therapeutic strategies.
Muzafar A. Macha, currently an Assistant Professor and Ramalingaswami Fellow at Watson-Crick Centre for Molecular Medicine, IUST, Kashmir, India, possesses a strong background in Biochemistry, Head and Neck Cancers (HNCs), and therapeutic modalities development. He previously served as a postdoctoral fellow and later as an Assistant Professor at the University of Nebraska Medical Centre (UNMC), leading an independent HNC research group. His notable contributions, recognized with multiple awards, include the identification of deregulated signaling pathways and innovative therapeutic strategies, published in esteemed journals.
Ajaz A. Bhat, a staff scientist at Sidra Medicine, Qatar, has an extensive background in peptide-based vaccine development, deregulated signaling pathways, and drug targets for various cancers. After earning his Ph.D. from AIIMS, India, he undertook postdoctoral training at Vanderbilt University Medical School, USA, expanding his understanding of colorectal, gastric, and esophageal cancers. His high-impact research, published in prestigious journals, earned him recognition as an outstanding researcher, and he actively serves on several immunology and cancer societies' editorial and review boards.
Surinder Kumar Batra, Chair of the Biochemistry and Molecular Biology Department at the University of Nebraska Medical Center (UNMC), USA, and Associate Director at Buffett Cancer Center, is renowned for his work on pancreatic cancer pathogenesis. His research focuses on mucins, glycoproteins with potential diagnostic and therapeutic applications. He has developed several genetically engineered models for cancer progression and received US patents on diagnostics and antibodies. With over 400 international peer-reviewed publications, he has trained 100+ scholars.
